

Technology Advisory Committee C Interests Register

Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer [ID4031]

Publication Date: 10 January 2024

Name	Role with NICE	Type of interest(s)	Description of interest(s)	Interest(s) declared	Comments
Elizabeth Thurgar	Committee Member	Indirect financial	Within the last 12 months Ms Thurgar has provided consultancy advice to AstraZeneca in unrelated indications (CKD and hyperkalaemia).	27.06.2023	It was agreed that her declaration would not prevent Ms Thurgar from participating in discussions on this appraisal.
Dr Kate Ren	Committee Member	Indirect financial	Dr Ren has provided a statistical methods consultancy service to AstraZeneca for a different treatment in a different disease area (Eplontersen for treating ATTRv-PN).	03.07.2023	It was agreed that her declaration would not prevent Dr Ren from participating in discussions on this appraisal.
Dr Mairéad McNamara	Clinical Expert	Direct financial	Dr McNamara has sat on an AstraZeneca advisory board and also spoke at an AstraZeneca symposium on treatment for patients with biliary tract cancer and the patient pathway (case-based discussion) at the World GI ESMO conference in June 2023.	16.12.2022	It was agreed that her declarations would not prevent Dr McNamara from providing expert advice to the committee.

Name	Role with NICE	Type of interest(s)	Description of interest(s)	Interest(s) declared	Comments
		Non-financial professional and personal	<p>Dr McNamara was a PI at The Christie NHS Foundation Trust for the TOPAZ clinical trial.</p> <p>Dr McNamara was involved in review of the TOPAZ clinical trial data and manuscript published in NEJM Evidence (co-author).</p>		
Professor John Bridgewater	Clinical Expert	Direct financial	Professor Bridgewater was invited to a virtual tumour board in gastric cancer (not biliary tract cancer) for AstraZeneca in December 2022.	23.12.2022	It was agreed that his declaration would not prevent Professor Bridgewater from providing expert advice to the committee.
Helen Morement	Patient Expert	Indirect financial	The organisation which Ms Morement founded, AMMF –The Cholangiocarcinoma Charity, has received sponsorship from AstraZeneca to support an education project and AMMF's 2023 Hybrid European Cholangiocarcinoma Conference.	18.07.2023	It was agreed that her declaration would not prevent Ms Morement from providing expert advice to the committee.